Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
My gray-haired, heavily moustachioed patient shot me a wry smile and a very slight nod under his cowboy hat. I got the message loud and clear. I reciprocated with a bit of a sigh. “Don’t worry. I’ll talk to him afterward.” The three-way conversation quickly resumed between the stoic patient, the eager medical student and…
Dr. Samantha Shapiro recounts her enthusiastic and ambitious early career in rheumatology—a path that culminated in burnout and a brave choice with new opportunities.
Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.
In comments to the CMS, the ACR advocated for telehealth flexibilities and fair reimbursement and pushed back on proposed efficiency adjustments and changes likely to increase administrative burden on practices.
The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
In today’s rapidly evolving healthcare landscape, rheumatologists face a growing number of challenges. Advocacy is a critical tool that helps protect and advance the profession and the patients it serves.
A phase 2 study from Spiera et al. found that patients with glucocorticoid-dependent PMR taking the antibody-drug conjugate ABBV-154 had a longer time to flare compared with those taking placebo, supporting further investigation.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.